If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

A spokesperson for the FDA said the agency is “considering a wide range of options to support American innovation." ...

Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.

In May, a BioSpace survey found that 56% of employed biopharma professionals are considering jobs outside the industry. Among the unemployed, that number jumps to 81%. In another pulse check, an ...

Communication must be viewed as more than the last step of the research process. It is the structure that makes scientific ...

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...

A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the ...

Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...

Nxera, which formerly went by Sosei, will also reprioritize its pipeline to focus on obesity, metabolic and endocrine ...

With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will file an approval application for Ziihera in the first half of 2026 for the treatment of ...